The mechanistic target of rapamycin complex-1 (mTORC1) coordinates regulation of growth, metabolism, protein synthesis and autophagy 1 . Its hyperactivation contributes to disease in numerous organs, including the heart 1,2 , although broad inhibition of mTORC1 risks interference with its homeostatic roles. Tuberin (TSC2) is a GTPase-activating protein and prominent intrinsic regulator of mTORC1 that acts through modulation of RHEB (Ras homologue enriched in brain). TSC2 constitutively inhibits mTORC1; however, this activity is modified by phosphorylation from multiple signalling kinases that in turn inhibits (AMPK and GSK-3β) or stimulates (AKT, ERK and RSK-1) mTORC1 activity 3-9 . Each kinase requires engagement of multiple serines, impeding analysis of their role in vivo. Here we show that phosphorylation or gain-or loss-of-function mutations at either of two adjacent serine residues in TSC2 (S1365 and S1366 in mice; S1364 and S1365 in humans) can bidirectionally control mTORC1 activity stimulated by growth factors or haemodynamic stress, and consequently modulate cell growth and autophagy. However, basal mTORC1 activity remains unchanged. In the heart, or in isolated cardiomyocytes or fibroblasts, protein kinase G1 (PKG1) phosphorylates these TSC2 sites. PKG1 is a primary effector of nitric oxide and natriuretic peptide signalling, and protects against heart disease 10-13 . Suppression of hypertrophy and stimulation of autophagy in cardiomyocytes by PKG1 requires TSC2 phosphorylation. Homozygous knock-in mice that express a phosphorylationsilencing mutation in TSC2 (TSC2(S1365A)) develop worse heart disease and have higher mortality after sustained pressure overload of the heart, owing to mTORC1 hyperactivity that cannot be rescued by PKG1 stimulation. However, cardiac disease is reduced and survival of heterozygote Tsc2 S1365A knock-in mice subjected to the same stress is improved by PKG1 activation or expression of a phosphorylation-mimicking mutation (TSC2(S1365E)). Resting mTORC1 activity is not altered in either knock-in model. Therefore, TSC2 phosphorylation is both required and sufficient for PKG1mediated cardiac protection against pressure overload. The serine residues identified here provide a genetic tool for bidirectional regulation of the amplitude of stress-stimulated mTORC1 activity.
(Extended Data Fig. 1d ), all consistent with increased autophagy. These changes are also induced by everolimus, a relatively selective mTORC1 inhibitor. In isolated cardiomyocytes that have been stimulated using endothelin-1 (ET1), cGMP activation of PKG1 increases autophagic flux as demonstrated by an increase in the number of red puncta (autolysosomes) in cells that express a tandem fluorescent reporter (LC3-II-GFP-RFP) 15 (Fig. 1c ) and by a higher increase in the expression of LC3-II in bafilomycin-A1-treated cardiomyocytes (Extended Data Fig. 2a ). The anti-hypertrophic effects of PKG1 are blunted by genetic silencing of autophagy related 5 (Atg5) (Extended Data Fig. 2b ). Thus, PKG1 activation suppresses cardiac mTORC1 signalling, blunts growth and enhances autophagy.
To determine the mechanism by which PKG1 induces suppression of mTORC1, adult rat cardiomyocytes were exposed to cGMP for 15 min, and lysates were analysed by phosphoproteomics. Among mTORC1-complex and -regulating proteins, mass spectrometry analyses identified phosphorylation at the first of two adjacent serines (S1364 and S1365 in humans; S1365 and S1366 in mice) in a highly conserved activation domain in TSC2, upstream of the GSK-3β and AMPK phosphorylation sites ( Fig. 1d and Extended Data Fig. 2c ). PKG1 is among the top kinases predicted to modify either S1364 or S1365 in human TSC2 (see PhosphoNET Kinexus; http://www.phosphonet.ca/kinasepredictor.aspx?uni=P49815&ps=S1364 and http://www.phosphonet. ca/kinasepredictor.aspx?uni=P49815&ps=S1365). Phosphorylation of TSC2(S1364) in humans has been reported previously 16, 17 . There are no reported human mutations in human TSC2(S1364); however, two children have been reported to have an S1365L mutation; each exhibited seizures but no tumours.
A commercial antibody against phosphorylated TSC2(S1365) in mice had been manufactured, but had no prior validation. Mouse embryonic fibroblasts (MEFs) show low levels of phosphorylation at baseline that increase with cGMP stimulation and are blocked by PKG1 inhibition using DT3 ( Fig. 1e and Extended Data Fig. 2d ). The antibody signal is present in the myocardium in vivo, increases after pressure overload and further increases after pressure overload and treatment with sildenafil but not after pressure overload and treatment with everolimus (Fig. 1f ). The level of phosphorylation correlates with PKG1 activity (Fig. 1g ). Analogous phosphorylation at TSC2(S1364) in humans is found in human non-failing myocardium and increases with dilated cardiomyopathy (Fig. 1h ). To test antibody specificity, rat cardiomyocytes were transfected with human wild-type haemagglutinin (HA)-tagged TSC2(WT), HA-tagged TSC2(S1364A) or HA-tagged TSC2(S1364E) at matched expression levels (Extended Data Fig. 2e ), and cells were stimulated with ET1 to activate PKG1 (Extended Data Fig. 3a, b) and induce TSC2 phosphorylation. The antibody signal increased only when TSC2(WT) was expressed ( Fig. 1i and Extended Data Fig. 3c ). Identical results were obtained when human TSC2 was was mutated at the adjacent S1365 (Extended Data Fig. 3d) ; thus, interference with either serine prevents PKG1 phosphorylation.
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PKG1 directly phosphorylates TSC2, as demonstrated by radiolabelling of TSC2 upon co-incubation of recombinant PKG1α-the primary cardiovascular isoform-with HA-TSC2 and [γ-32 P]ATP ( Fig. 1j ). Radiolabelling of TSC2 also occurred when human HA-TSC2(S1364A) (Fig. 1j ) or human Flag-TSC2(S1365A) (Extended Data Fig. 3e ) was used, indicating that additional phosphorylation sites exist. We also tested whether PKG1α (the primary cardiovascular isoform) directly modifies TSC2 in the presence of proteins isolated from whole-cell lysates using mutated PKG1α (M438G) 18 -which uniquely binds to modified and enlarged sulfonated ATP 19 . This assay revealed a TSC2 thiophosphate ester (PKG1α phosphorylation) in TSC2(WT) and both S1364A and S1365A mutations (Extended Data Fig. 3f ).
We next tested the functional importance of the serine residues. Rat cardiomyocytes were transfected with TSC2(WT), human HA-TSC2(S1364A) or human HA-TSC2(S1364E) and then stimulated with ET1 for 48 h (Fig. 2a, b ). Basal expression of rat Nppb mRNA (a hypertrophy biomarker) was low, regardless of which TSC2 construct was overexpressed. ET1 increased Nppb expression the most in human TSC2(S1364A)-expressing cells and the least in human TSC2(S1364E)-expressing cells, each compared to TSC2(WT) ( Fig. 2a ). Nppb expression decreased with PKG1 activation only in TSC2(WT)-expressing cells, consistent with the lack of phosphorylation of human TSC2 at S1364 with either mutation (Fig. 1i ). Very similar results were obtained when human TSC2 was mutated at S1365A or S1365E (Extended Data Fig. 4a ), indicating that mutations in either serine alone are sufficient to induce a similar biological response. In comparison to expression of TSC2(WT), TSC2(S1365A) expression increased whereas TSC2(S1365E) expression attenuated mTORC1 activity after stimulation using ET1; neither mutation had an effect at baseline. LC3-II protein expression increased and p62 expression decreased after expression of TSC2(S1365E), supporting enhanced autophagy; the opposite occurred after expression of TSC2(S1365A). This was observed regardless of which serine was mutated (human TSC2(S1364): Fig. 2b and Extended Data Fig. 4b ; human TSC2(S1365): Extended Data Fig. 4c, d ). An increase in the number of red LC3-II punctae indicate that there is an increase in autophagic flux with expression of TSC2(S1365E) (Fig. 2c ). Phenylephrine treatment mimicked the effects of ET1 (Extended Data Fig. 5a ), and expression of TSC2(S1364A) depressed the modulation of PKG1 of LC3-II and p62 (Extended Data Fig. 5b ). Therefore, mutants with substitutions at either of the two adjacent serine residues in TSC2 either amplify or attenuate stress-stimulated mTORC1 regulation, and the effects of PKG1 on growth and autophagy are either markedly impaired (S1365A) or mimicked (S1365E) by single point mutations in either residue. TSC2 predominantly modulates mTORC1 by regulating RHEB-GTP binding, and silencing of Rheb blocked ET1-stimulated activation of mTORC1 in TSC2(WT)-and TSC2(S1365A)-expressing rat cardiomyocytes. TSC2(S1365E)-expressing cells exhibited low mTORC1 activity despite ET1 stimulation, regardless of whether Rheb was Data are mean ± s.e.m.; n = 11-12 per group. i, The phosphorylationspecific antibody detects phosphorylated TSC2 in ET1-stimulated cardiomyocytes that overexpress human HA-TSC2(WT) (WT) but not human HA-TSC2(S1364A) (SA) or human HA-TSC2(S1364E) (SE). M, marker. n = 3 replicates; a summary of the data is shown in Extended Data Fig. 3d . j, TSC2 phosphorylation occurs by recombinant PKG1α, as shown by autoradiography of human HA-TSC2(WT) and HA-TSC2(S1364A) (top). Bottom, immunoblots for HA and TSC2. n = 8 biologically independent replicates.
Letter reSeArCH silenced or not ( Fig. 2d and Extended Data Fig. 5c ). The serine residues are proximate to residues that are targeted by AMPK and GSK-3β, the latter of which requires AMPK co-activation of TSC2 9 . To test whether the S1365A mutation prevents TSC2-mTORC1 control through AMPK, Tsc2 knockout MEFs that expressed TSC2(WT), TSC2(S1365A) or an empty vector were exposed to ET1 followed by treatment with 2-deoxyglucose (2-DG), which inhibits glycolysis to stimulate AMPK. Tsc2 knockout MEFs showed constitutive activation of mTORC1 that was reasonably insensitive to 2-DG. Expression of TSC2(WT) or TSC2(S1365A) reduced the activity of mTORC1, and this activity was further depressed similarly in each of these two groups by 2-DG in concordance with phosphorylation of the AMPK-phosphorylation site at S1387 ( Fig. 2e-h ). Thus, a silencing or phosphomimetic TSC2 mutation at human S1364 or S1365 does not impede energy-responsive inhibition of mTORC1 associated with AMPK-phosphorylation at neighboring TSC2 sites.
Mice with a global Tsc2 S1365A knock-in mutation were generated using CRISPR-Cas9 gene editing ( Fig. 3a and Extended Data Fig. 6a ) to assess the role of TSC2 in vivo. Mice were born at normal Mendelian ratios, grew and developed normally, and had similar cardiac structure and function compared to their littermate controls (Extended Data Table 1 ).
In addition, the expression levels of myocardial TSC2 were similar to those in littermate controls (Extended Data Fig. 6b ). Heterozygote (Tsc2 S1365A/WT ), homozygote (Tsc2 S1365A/S1365A ) and control (Tsc2 WT/WT ) mice were subjected to pressure overload, and randomized to either treatment with vehicle or sildenafil. Mortality after pressure overload in vehicle-treated mice was markedly higher in Tsc2 S1365A/WT and Tsc2 S1365A/S1365A mice compared to Tsc2 WT/WT mice. Notably, sildenafil prevented the increase in mortality in Tsc2 S1365A/WT but not Tsc2 S1365A/S1365A mice (Fig. 3b ). Pressure-overload-induced hypertrophy and dysfunction of the heart and increased lung weight were more pronounced in Tsc2 S1365A/WT and Tsc2 S1365A/S1365A mice compared to Tsc2 WT/WT mice, and sildenafil only reversed these effects of pressure overload in Tsc2 S1365A/WT and Tsc2 WT/WT mice (Fig. 3c, d and Extended Data Fig. 6c ). Activity of mTORC1 and aggregation of myocardial proteins were greater and autophagy (increased p62 expression and decreased LC3-II expression) was depressed following pressure overload in Tsc2 S1365A/WT and Tsc2 S1365A/S1365A mice compared to Tsc2 WT/WT mice, and this reduction in autophagy was also reversed by sildenafil in the hearts of Tsc2 S1365A/WT and Tsc2 WT/WT , but not Tsc2 S1365A/S1365A , mice (Fig. 3e , f and Extended Data Fig. 6d , e). These findings were similar in both male and female mice. Activation of mTOR complex-2 
2 | TSC2(S1365A) and TSC2(S1365E) bidirectionally regulate mTORC1 growth hormone activation to control cardiomyocyte hypertrophy and autophagy. a, Effect of human TSC2(WT), TSC2(S1364E) and TSC2(S1364A) on prohypertrophic Nppb expression in isolated cardiomyocytes treated with or without sildenafil stimulated with vehicle or ET1. n = 6 biologically independent samples for each condition. Data are mean ± s.d.; one-way ANOVA with Tukey multiple comparisons test within TSC2 genotypes: *P < 1 × 10 −6 versus other groups within each TSC2 genotype; two-way ANOVA between genotypes, ET1 versus ET1 and sildenafil: P < 1 × 10 −6 for sildenafil and TSC2 genotype interaction; Tukey multiple comparisons tests: † P < 1 × 10 −6 versus WT treated with ET1 and S1364A treated with ET1; ‡ P = 4 × 10 −6 versus WT treated with ET1; # P < 1 × 10 −6 versus ET1 treated with sildenafil for other genotypes. b, Example immunoblots for phosphorylated and total p70S6K, 4E-BP1, total p62 and LC3-II from same experiments as in a. A summary of the results is shown in Extended Data Fig. 4b . n = 4-6 biologically independent samples. c, Confocal image and summary data of autophagic flux (using the LC3-II-GFP-RFP reporter) in TSC2(WT)-, TSC2(S1365A)-or TSC2(S1365E)-expressing cardiomyocytes stimulated with or without ET1. n = 6 biologically independent experiments; data are mean ± s.e.m.; one-way ANOVA, Sidak multiple comparison test. For both green and red dots: *P ≤ 8 × 10 −5 versus corresponding vehicle; for red dots: † P = 0.014 versus vehicletreated and TSC2(S1365A) and ET1-treated and TSC2(WT); P < 1 × 10 −6 versus ET1-treated and TSC2(S1365E); # P < 1 × 10 −6 versus ET1treated and TSC2(WT); for green dots: ‡ P = 0.003 versus ET1-treated and TSC2(WT), P < 1 × 10 −6 versus ET1-treated and TSC2(S1365E). d, mTORC1 modulation by TSC2(S1365A) requires RHEB. Neonatal rat cardiomyocytes transfected with Rheb (siRheb) or scrambled siRNA (indicated by a '−' in figure) , cotransfected with human TSC2(WT), TSC2(S1365E) or TSC2(S1365A) plasmids were stimulated with ET1. Immunoblots for RHEB, phosphorylated p70S6K and total p70S6K are shown. n = 4 biologically independent experiments. A summary of the data is shown in Extended Data Fig. 5c . e, Tsc2 knockout MEFs infected by adenovirus expressing empty vector, human TSC2(WT) or TSC2(S1365A) were exposed to ET1 to stimulate mTORC1 and then treated with 2-DG to suppress mTOR1 by metabolic inhibition to activate AMPK. mTORC1 activation is blunted by 2-DG in TSC2(WT)-or TSC2(S1365A)-expressing cells and correlates with increased phosphorylation at S1387 (the AMPK site). Experiments were replicated five times. f-h, Summary analysis of the experiment shown in e. n = 10 biologically independent samples; data are mean ± s.e.m. KO, knockout. f, Two-way ANOVA with Tukey multiple comparisons test, *P < 1 × 10 −6 versus Tsc2 knockout in corresponding treatment group; P = 0.6 for the interaction between 2-DG and genotype. g, One-way ANOVA with Tukey multiple comparisons test, ***P < 1 × 10 −6 , **P = 0.0002, *P = 0.001 versus Tsc2 knockout. h, **P = 0.004 and *P = 0.008 versus without 2-DG.
was unaltered by the TSC2(S1365A) mutation (Extended Data Fig. 7a ). Tsc2 S1365A/S1365A mice randomized to everolimus treatment (compared to vehicle, each starting three days before pressure overload) showed similar levels of mortality ( Fig. 4a ) and heart disease (Fig. 4b , c) after pressure overload as in wild-type controls, and had increased levels of autophagy (Extended Data Fig. 7b ), supporting a role for mTORC1 hyperactivation, which is induced by expression of TSC2(S1365A). Together, these results show that TSC2(S1365A) in mice acts as an autosomal dominant mutation that amplifies stress-stimulated, but not baseline, mTORC1 activity in vivo. In addition, we show that pS1365 is required for PKG1-mediated mTORC1 suppression and amelioration of heart disease induced by pressure overload. Tsc2 S1365E knock-in mice were also generated (Extended Data Fig. 8a ) to test whether a phosphorylation-mimicking mutation confers effects that are opposite to the S1365A mutation. Mice were also born at normal Mendelian ratios, and had normal cardiac morphology and function (Extended Data Table 1 ). In contrast to Tsc2 S1365A/WT and Tsc2 S1365A/S1365A mice, both Tsc2 S1365E/WT and Tsc2 S1365E/S1365E mice were markedly protected against pressure overload, and showed minimal hypertrophy and better heart function compared to Tsc2 WT/WT controls ( Fig. 4d, e ). Baseline mTORC1 activity after expression of TSC2(S1365E) is similar to TSC2(WT), but remains low after pressure overload, whereas expression of LC3-II increases and p62 decreases ( Fig. 4f and Extended Data Fig. 8b ). In vivo autophagic flux is higher in Tsc2 S1365E/S1365E mice and lower in Tsc2 S1365A/S1365A compared to wild-type mice (Extended Data Fig. 8c ). Both Tsc2 S1365E/S1365E and Tsc2 S1365E/WT mice also have reduced aggregation of myocardial proteins (Fig. 4g ).
Both TSC2(S1365A) and TSC2(S1365E) affect stress-induced but not basal mTORC1 activity or in vivo cardiac physiology. This is in contrast to cardiomyocyte-targeted Tsc2 deletion, which leads to constitutive activation of mTORC1 that induces heart disease 20 , and genetic mTOR or mTORC1 suppression-which induces heart failure and early lethality 21, 22 . The lack of a basal phenotype in both knock-in models is notable, as these mutations are found in all cells, highlighting an advantage of modulating mTORC1 through TSC2 rather than by targeting the mTORC1 complex itself. Previous in vitro studies using TSC2 mutants that silenced (Ser to Ala substitution) kinase-targeted phosphorylation Sham PO PO + Sil Tsc2 WT/WT Tsc2 S1365A/WT Tsc2 S1365A/S1365A a b c d e f Tsc2 WT/WT PO (9) Tsc2 S1365A/WT PO (11) Tsc2 S1365A/S1365A PO (15) Tsc2 WT/WT PO + Sil (7) Tsc2 S1365A/WT PO + Sil (6) Tsc2 S1365A/S1365A PO + Sil (17) PO Sil | TSC2(S1365A) knock-in mice have exacerbated hypertrophy and mortality from pressure overload, and disease progression in homozygous knock-in cannot be ameliorated by PKG1 activation. a, Strategy and guide RNA for CRISPR-Cas9 generated mouse TSC2(S1365A) (SA) knock-in mice. gRNA, guide RNA; ssODN, singlestranded oligodeoxynucleotide. b, Percentage survival of Tsc2 S1365A/WT , Tsc2 S1365A/S1365A and Tsc2 WT/WT mice subjected to sham surgery or pressure overload treated with vehicle or sildenafil. Sample sizes per group are indicated. log-rank Mantel-Cox test, *P = 0.04 combined Tsc2 S1365A/WT and Tsc2 S1365A/S1365A versus Tsc2 WT/WT mice treated with vehicle; † P = 0.03 Tsc2 S1365A/WT treated with sildenafil versus Tsc2 S1365A/WT without sildenafil. c, Cross-sections of left ventricles stained with Masson's trichrome from Tsc2 S1365A/WT , Tsc2 S1365A/S1365A and Tsc2 WT/WT mice subjected to sham surgery or pressure overload and treated with vehicle or sildenafil. Experiments were repeated at least six times for each condition. d, Analyses of heart weight (HW) and lung weight (LuW) normalized to tibial length (TL) and fractional shortening show significant suppression of hypertrophy and lung congestion with sildenafil treatment in hearts from Tsc2 S1365A/WT and Tsc2 WT/WT mice but no effect in pressureoverloaded hearts from Tsc2 S1365A/S1365A mice. Number of biologically independent replicates: n = 5 for Tsc2 S1365A/WT pressure overload, n = 6 for Tsc2 S1365A/WT and Tsc2 S1365A/S1365A pressure overload and sildenafil, n = 7 for Tsc2 S1365A/S1365A and Tsc2 WT/WT pressure overload and sildenafil and n = 8 for Tsc2 WT/WT pressure overload; data are mean ± s.d.; one-way ANOVA with Tukey multiple comparison test, **P < 1 × 10 −6 and *P = 0.0004 versus pressure overload without sildenafil and Tsc2 S1365A/S1365A pressure overload with sildenafil; ### P = 0.0001, # P = 0.04 and ## P = 0.001 versus Tsc2 WT/WT without sildenafil; † P = 0.01 and † † P = 0.0001 versus Tsc2 WT/WT pressure overload; § P = 0.0006 and § §P < 1 × 10 −6 versus Tsc2 WT/WT pressure overload. e, Immunoblots for phosphorylated and total p70S6K as well as p62 and α-tubulin from myocardium of Tsc2 WT/WT , Tsc2 S1365A/WT and Tsc2 S1365A/S1365A mice after sham surgery, pressure overload or pressure overload treated with sildenafil. Experiments were repeated once with identical results, a summary of the results (n = 4 per condition) can be found in Extended Data Fig. 6e , f. f, Analysis of myocardial protein aggregation in Tsc2 S1365A/WT or Tsc2 S1365A/S1365A mice after sham surgery, pressure overload and pressure overload treated with sildenafil. Data are mean ± s.d.; biological replicates are as shown in d. One-way ANOVA with Tukey multiple comparisons test: *P ≤ 0.00008 versus respective sham in each group; § P < 0.0003 versus respective pressure overload; † P < 0.0003 versus Tsc2 WT/WT pressure overload and sham; ‡ P < 1 × 10 −6 versus pressure overload and sildenafil for the other two genotypes.
Letter reSeArCH sites for AMPK 8 , ERK1/2 4 , AKT 5 and GSK-3β 9 each found that these mutations altered the basal activity of mTORC1. Alternatively, substituting two serines in TSC2 with aspartic acids to mimic ERK1/2 phosphorylation stimulated mTORC1 activity and cell growth 4 . These effects also differ from modulation by human TSC2(S1364) (or TSC2(S1365)), which act more as an amplifier (when either one is mutated to an alanine) or attenuator (when mutated to a glutamic acid) of mTORC1 co-stimuli. Moreover, models using TSC2(S1365A) and TSC2(S1365E) afford selective control of mTORC1 activity, as TSC2 potently regulates growth factors (or pressure overload, a multifactorial stress), but not metabolic signalling, through AMPK. Similar selectivity may apply to other TSC2 kinase regulators, but this remains unknown. Here we use Tsc2 knock-in mice as an in vivo model to alter TSC2 phosphorylation; however, whether multi-site silencing and/or mimetic mutants of other TSC2-regulating kinases yield similarly benign phenotypes at baseline remains to be determined.
The TSC2 mutations (S1364A, S1365A, S1364E and S1365Enumbering based on the human sequence) each modify mTORC1regulated growth and autophagy, as shown by multiple cell-based assays in which TSC2 is mutated at either of these two adjacent serine residues. This is further confirmed in vivo by pressure overload in heterozygous or homozygous TSC2(S1365A) or TSC2(S1365E) knock-in mice and homozygous TSC2(S1365A) mice treated with everolimus.
Although PKG1 also modulates pathological growth through other pathways 11 , our results show that PKG1 also modulates autophagy. In Tsc2 S1365A/S1365A mice subjected to pressure overload, sildenafil failed to alter expression of LC3-II and p62 or aggregation of myocardial proteins, supporting a key role of PKG1-TSC2 modulation at mouse TSC2(S1365). Whether genetically preventing autophagy abrogates PKG1 amelioration of heart disease in vivo, and if so whether it requires human TSC2(S1364) or TSC2(S1365), remains to be tested.
Our results identify PKG1 as a direct mediator of post-translational regulation of TSC2(S1364) and TSC2(S1365) (numbering based on the human sequence). The fact that PKG1 does not phosphorylate TSC2 regardless of which residue is mutated, and that cell behaviour after mutations of either serine 1364 or 1365 (based on the human sequence) to an alanine or glutamic acid yield nearly identical results supports tight inter-regulation between them. Although additional PKG1 sites on TSC2 are suggested by our studies, the data indicate that either of the two identified sites is sufficient. Other kinases may also target these residues, as phosphorylation of mouse TSC2 at S1365 was first reported in a proteomic study of TSC2 suppressing proteins (ERK and p90S6K), and is modified by phorbol ester, a non-specific protein kinase C activator 16 . The previous study did not perform any functional analyses, and importantly, phorbol ester and more specific PKC activators activate mTORC1 23,24 , in contrast to PKG1. The findings Tsc2 S1365A/S1365A PO + Evl | Everolimus rescues TSC2(S1365A) mice, and TSC2(S1365E) knock-in mice are protected against hypertrophy, dysfunction and mTORC1 hyperactivation following pressure overload. a, Percentage survival of Tsc2 S1365A/S1365A pressure-overloaded mice treated with or without everolimus. A log-rank Mantel-Cox test was used; the number of mice per group is shown. b, Echocardiograms show normalized left ventricular function in everolimus-treated mice. n = 4, 9, 8 for sham, pressure overload and pressure overload treated with everolimus. c, The increase in heart and lung weight normalized to tibial length induced by pressure overload is reversed by everolimus treatment in Tsc2 S1365A/S1365A mice; data are mean ± s.d.; Kruskal-Wallis test with Dunn's multiple comparisons test versus pressure overload alone: **P = 0.01 versus sham and ***P = 0.001 versus pressure overload and everolimus; *P = 0.021 versus sham and ****P = 0.0005 versus pressure overload and everolimus. d, Echocardiograms of Tsc2 S1365E/WT and Tsc2 S1365E/S1365E mice subjected to 6 weeks of pressure overload display improved function despite pressure overload. Experiments were repeated 7-8 times per group. e, Regression of heart weight/tibial length and percentage fractional shortening versus the difference in left ventricular aorta pressure (load). P values are for group effect between Tsc2 WT/WT versus Tsc2 S1365E/WT and Tsc2 S1365E/S1365E mice by analysis of covariance (ANCOVA). f, Immunoblots of phosphorylated and total p70S6K, p62 and corresponding α-tubulin, and LC3-II and corresponding total protein (n = 6, 6, 4, 4, 4 and 4 biologically independent samples, respectively). A summary of the data is shown in Extended Data Fig. 8b . g, Analysis of myocardial protein aggregation induced by pressure overload in Tsc2 S1365E/WT and Tsc2 S1365E/S1365E mice. Data are mean ± s.d.; n = 6 biologically independent experiments; twoway ANOVA, P < 1 × 10 −6 for effect of pressure overload, genotype and the interaction; Tukey multiple comparisons test, *P = 0.00002 versus respective sham; † P = 0.00002 versus Tsc2 S1365E/WT and Tsc2 S1365E/S1365E pressure overload, ‡ P = 0.0003 versus Tsc2 S1365E/WT pressure overload. that pathological stress stimulates TSC2 phosphorylation in cardiomyocytes and the myocardium along with activation of mTORC1, whereas preventing this phosphorylation by substituting alanine for the PKG1-modified serines amplifies the pathology, supports a role for the phosphorylation of TSC2 at this site as negative feedback on mTORC1 activity. The protective effects induced by substituting serine with glutamic acid or the effects of more selective phosphorylation by PKG1 support this idea further. Mammalian cells ubiquitously express TSC2, mTOR and related mTOR-complex proteins, and many cell types also express PKG1. Therefore, our data have implications beyond the heart, including to potential therapeutic roles for PKG1 activators in diseases in which altered modulation of mTORC1 is present and/or desired. Furthermore, genetic modulation of the identified phosphorylation sites provides a method of mTORC1 control with potential use in adoptive cell therapies, by providing a more nuanced and flexible method of mTORC1 regulation.
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MEthodS
Data reporting. While no statistical methods were used to predetermine sample size for each assay, we based the group size whenever possible on prior experience with similar assays and variance. The surgeon who performed pressure overload in the mice, and sonographer who obtained and interpreted the echocardiographic images were fully blinded to genotype and/or treatment. All tissues were isolated by an independent investigator with no knowledge of the genotype. Subsequent molecular and biochemical studies were performed with knowledge of the genotype from which the extracts had been obtained. Animal models. Mice expressing global TSC2 knock-in mutations MmTSC2(S1365A) or MmTSC2(S1365E) (Fig. 3a and Extended Data Figs. 6a,  8a) were newly generated using CRISPR-Cas9 gene editing (Transgenic Core Laboratory, Johns Hopkins University). Tsc2 guide RNA was designed using an algorithm developed by V. Ranganathan 25 , and cloned into pSpCas9(BB)-2A-Puro (PX459) V2.0 (a gift from F. Zhang, Addgene plasmid 62988) and pUC57-sgRNA (a gift from X. Huang, Addgene plasmid 51132) expression vectors. DNA cleavage was tested in mouse N2a cells using the Surveyor Mutation Detection kit (Integrated DNA Technologies) according to the previously published protocol 26 . In vitro transcription was performed for both Cas9 (from a modified pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid, originally a gift from F. Zhang, Addgene plasmid 42230) and guide RNA using the Ambion mMESSAGE mMACHINE kit and NEB HiScribe T7 High Yield RNA Synthesis kit, respectively. Single-sequence oligodeoxynucleatide (ssODN) for the S1365A or S1365E point mutations were purchased from Integrated DNA Technologies. C57BL/6J blastocyst injections were performed by members of the Johns Hopkins Transgenic Mouse Core Laboratory with a mix consisting of: 25 ng μl −1 Cas9. 12.5 ng μl −1 guide RNA and 25 ng μl −1 ssODN. We received five founder mice that were positive for the Tsc2 S1365E transgene and three founder mice that were positive for the Tsc2 S1365A transgene. Both colonies of mice were backcrossed with mice on a C57BL/6J background, generating mice with a 98.5% (S1365E) and 99.3% (S1365A) purity. The genetic backgrounds of mice were assessed at DartMouse Speed Congenic Core Facility at the Geisel School of Medicine at Dartmouth. DartMouse uses the Illumina Infinium Genotyping Assay to analyse a custom panel of 5,307 single-nucleotide polymorphisms (SNPs) spread throughout the genome. The raw SNP data were analysed using DartMouse's SNaP-MaP and Map-Synth software, allowing the determination for each mouse of the genetic background at each SNP location. We maintained each colony with the breeding strategy of a heterozygous male and a heterozygous female, yielding knock-in homozygous mice, knock-in heterozygous mice, and littermate wild-type mice at a 25:50:25 ratio. Pressure-overload model. Pressure overload was induced by trans-aortic constriction as previously described 10 . Sham controls underwent similar surgery without ligature constriction. Age-matched (2-3 months) and weight-matched (generally, 25-30 g) littermates were randomly allocated into pressure overload or sham surgery groups with male and female mice equally represented. Mice were followed for up to 6 weeks after pressure overload, in some instances, co-treated with everolimus (Sigma; oral gavage, 10 mg kg −1 day −1 ) or sildenafil (Pfizer or Wako Pure Chemical Industries, 200 mg kg −1 day −1 mixed in soft diet, Bioserv) 12 or appropriate matched vehicle. Drug treatment started either 1 week following pressure overload, or several days before pressure overload. All of the protocols were approved by the Johns Hopkins Medical Institutions Animal Care and Use Committee. The studies were in compliance with all ethical regulations. Conscious mouse echocardiography. Intact heart morphology and function were measured in conscious mice by serial M-mode transthoracic echocardiography (VisualSonics Vevo 2100, 18-38 MHz transducer; FUJIFILM VisualSonics). Images were obtained and analysed using VisualSonics image software, by an individual blinded to the conditions of the animal. TSC2 expression plasmids and adenovirus. An N-terminally Flag-tagged human TSC2 expression plasmid was provided by B. Manning (Harvard University) and is available from Addgene (Plasmid 14129). Based on this, we further generated five new constructs, one in which Flag was replaced by an HA sequence (also at the N terminus), and then each wild-type vector was further modified to generate human HA-TSC2(S1364A), HA-TSC2(S1364E), Flag-TSC2(S1365A) and Flag-TSC2(S1365E). Adenovirus was also developed expressing the Flag-tagged wildtype sequence or human TSC2(S1365A) or TSC2(S1365E) sequences (Welgen) and used for studies involving Tsc2 knockout and Tsc2 wild-type MEFs. These cells lines were provided by B. Manning as first generated by D. Kwiatkowski 27 . Neonatal rat cardiomyocyte studies. Neonatal rat cardiomyocytes (NRCMs) were isolated and cultured at 1 million cells per well in six-well plates for 24 h in DMEM with 10% FBS and antibiotics before study, as previously described 10 . Hypertrophy was stimulated with ET1 (10 nM, Sigma), phenylephrine (100 μM, Sigma) for either 15 min or 48 h in serum-free DMEM supplemented with 0.1% insulin-transferrin-selenium (Life Technologies). Studies were also performed in NRCMs first transfected with plasmids expressing TSC2(WT), TSC2(S1365A) or TSC2(S1365E) (human S1364 or human S1365) (5 μg per well), using Takara Clontech Xfect as per the manufacturer's protocol. Cells were provided 24 h before exposure to stimulation with ET1 or vehicle in combination with other reagents as described in the study. Tsc2 knockout MEFs. MEFs were cultured in DMEM supplemented with 10% FBS and 1% antibiotics until 50-60% confluence, at which time the cells were transfected with Tsc2 constructs or empty vector, or infected with adenovirus expressing TSC2(WT), TSC2(S1365A) or TSC2(S1365E). Expression vectors used a CMV promoter. After an additional 24 h of culturing, transfected MEFs were treated with 8-bromo-cGMP (100 μM), DT3 (1 μM), 2-DG (100 μM) or vehicle control. Human myocardium analysis. Human myocardium was obtained in accordance with institutional review board approvals at Johns Hopkins University and the University of Pennsylvania. The use of human subject material was in compliance with all ethical regulations. Failing human hearts were obtained at the time of explant surgery, and non-failing controls at time of the collection of other organs. Left ventricular free wall tissue was collected at the University of Pennsylvania in ice-cold cardioplegia and rapidly frozen in liquid nitrogen. Informed consent was obtained from failing heart human tissue donors. The family or legal representative provided consent for organ collection from deceased donor controls. For the non-failing controls, the age was 52.8 ± 15.4, 6 males, 6 females, no clinical history of heart failure; for the heart failure group, the mean age was 51.3 ± 12.1, 8 males, 4 females (P = not significant for sex distribution between groups), and all were patients with non-ischaemic dilated cardiomyopathy with severe left ventricular dysfunction who then underwent cardiac transplantation. Immunoblot analysis. Whole-cell lysate was extracted (Cell Signaling Technology, 9803) and the protein concentration was determined by BCA method (Pierce). Samples were prepared in SDS Tris-glycine buffer (Life Technologies) and run on Novex 8-16% Tris-glycine gels (Life Technologies) or TGX 7.5% and 4-20% Trisglycine gels (Bio-Rad) and blotted onto a nitrocellulose membrane. The following primary antibodies were used in this study: phosphorylated (phospho)-AKT (S473) (9271, lot 14, used at 1:1,000), AKT (9272, lot 28, used at 1:1,000), phospho-p70S6K (T389) (9205, lot 21, used at 1:1,000), p70S6K (9202, lot 20, used at 1:1,000), phospho-4E-BP1 (S65) (9451, lot 14, used at 1:1,000), 4E-BP1 (9452, lot 12, used at 1:1,000), phospho-ULK1 (S757) (1420, clone D706U, lot 4, used at 1:1,000), ULK1 (8054, clone D8H5, lot 5, used at 1:1,000), phospho-FOXO1/3 (9464, lot 7, used at 1:2,500), FOXO1 (2880, clone C29H4, lot 11, used at 1:3,000), phospho-NRDG-1 (3217, clone D98G11, lot 3, used at 1:5,000), NRDG-1 (9395, clone D6C2, lot 1, used at 1:1,000), GAPDH (2118, clone 14C10, lot 10, used at 1:1,000), RHEB (13879, clone E1G1R, lot 1, used at 1:1,000), phospho-TSC2 (S1387) (5584, lot 5, used at 1:1,000), TSC2 (3612, clone D93F12, lot 5, used at 1:1,000) and α-tubulin (3873, clone DM1A, lot 12, used at 1:1,000) (Cell Signaling Technology), phospho-TSC2 (S1365) (120718, lot NFSA12072OAH, used at 1:500) (NovoPro Labs), LC3 (ab192890, lot GR321-3, used at 1:1,000), thiophosphate ester (ab92570, lot GR237393-18, used at 1:5,000) and p62 (ab109012, lot GR12843-70, used at 1:1,000) (Abcam), Flag (F3165, lot SLBK1346V, used at 1:1,000), ubiquitin (SAB4503053, lot 310385, used at 1:1,000) (Sigma) and a total protein stain (926-11016, lot C80522-02, used at 5 ml per membrane) (Li-Cor). Antibody binding was visualized by infrared imaging (Odyssey, Licor) and quantified with Licor Image Studio Software 3.1. Gene expression by quantitative RT-PCR. Total RNA isolated from left ventricular myocardium or cultured NRCMs (TRIzol Reagent, Invitrogen), was reverse transcribed to cDNA (High Capacity RNA-to-cDNA Kit, Applied Biosystems, Life Technologies) and underwent PCR amplification using TaqMan probes for atrial natriuretic peptide (Nppa) (mouse Mm01255747_g1, rat Rn00664637_g1), B-type natriuretic peptide (Nppb) (mouse Mm01255770_g1, rat Rn00580641_m1), regulator of calcineurin 1 (Rcan1) (mouse Mm01213406_m1, rat 01458494_m1), tuberous sclerosis complex 2 (Tsc2) (mouse Mm00442004_m1, rat Rn00562086_m1), or glyceraldehyde-3-phosphate dehydrogenase (Gapdh) (mouse 99999915_g1, rat Rn01775763_g1) (Applied Biosystems). The threshold cycle value was determined using the crossing point method and samples were normalized to Gapdh for each run. Bafilomycin A1 autophagy-flux assay. For in vitro studies, NRCMs were cultured as described above, stimulated with cGMP (50 μM) for 15 min, and then treated with either vehicle or bafilomycin A1 (BFA, 1 μM) (Sigma) for 3 h. For in vivo studies, Tsc2 WT/WT , Tsc2 S1365A/S1365A and Tsc2 S1365E/S1365E mice received two intraperitoneal injections of BFA (3 μM kg −1 ) 90 min apart. The myocardium was collected 90 min after the second injection, and protein extracts were analysed by immunoblot for expression of LC3-II. The relative increase in expression with versus without BFA indexes autophagic flux. Protein aggregation assays. Protein aggregation was measured using Proteostat (Enzo, ENZ-51023) following the manufacturer's instructions. Ventricular myocardial lysate (Cell Signaling lysis buffer) was obtained, protein concentration assayed and 10 μg protein loaded into a 96-well microplate and protein aggregates were analysed using the Proteostat assay kit (Enzo Life Sciences) following the Letter reSeArCH manufacturer's instructions. After background subtraction, values were normalized to wild-type sham.
For a second assay, 1 mmol l −1 phenylmethanesulfonyl fluoride and a phosSTOP tablet (Sigma-Aldrich/Roche) were added to myocardial lysates. This was centrifuged at 8,000g in 4 °C for 10 min, the supernatant (soluble fraction) was extracted and the pellet was resuspended in insoluble extraction buffer (40 mmol l −1 Tris HCl (pH 8.8), 1% SDS and 8% glycerol), boiled for 5 min and recentrifuged at 3,000g for 5 min. Then, 2.5 μg of the supernatant (insoluble fraction) was filtered through a nitrocellulose membrane (pore diameter, 0.22 μm, Millipore) using a dot-blot apparatus (BioRad) and immunoprobed for ubiquitin and α-tubulin. Tandem fluorescent LC3-II autophagic flux assay. NRCMs were infected with an adenovirus (10 MOI) expressing a tandem fluorescent (GFP-RFP) tagged LC3-II 15 . This expresses LC3-II with both green and red fluorescent tags as the autophagosomal membrane is forming; but upon merging with the acidic lysosome (autolysosome), the GFP signal is quenched, leaving RFP. The increase in RFP provides a marker of autophagic flux. In some studies, cardiomyocytes were further transfected with a plasmid encoding TSC2(WT), TSC2(S1365A) or TSC2(S1365E) and stimulated for 48 h with ET1 (10 nM). Dot counts for both colours per cell were determined using Image J software (version 1.52a, NIH). In vitro PKG1 activity. PKG1 activity was assessed by in vitro colorimetric assay (Cyclex, CY-1161, MBL International) following the manufacturer's instructions.
The assay provides cGMP substrate and a kinase-specific peptide target to assess phosphorylation activity. Proteomic analysis of PKG1 phosphokinome. Freshly isolated adult cardiomyocytes were obtained from male Wistar rats as previously described 28 , and divided into two aliquots, each relaxed in Tyrode buffer (140 mM NaCl, 5 mM KCl, 10 mM HEPES, 1 mM glucose, 1 mM MgCl 2 , 1 mM Ca 2+ , pH 7.45). Cells were then exposed to 1 mM 8-bromo-cGMP or Tyrode solution for 10 min to stimulate intracellular PKG1 activity. Cells were then centrifuged for 1 min at 1,000g, the supernatant was removed and the pellet frozen in liquid nitrogen and stored at −80 °C. Frozen samples (n = 3 per group) were then lysed in an 8 M urea and 0.5% SDS solution with brief sonication, and the protein concentration was determined by the BCA method. For each sample, 200 μg of total protein was digested with trypsin/Lys-C protease mixture (Promega), samples were desalted on 10 mg Oasis HLB cartridges (Waters) and eluted in 300 μl of 80% acetonitrile (ACN), 5% trifluoroacetic acid, 1 M glycolic acid and enriched by titanium dioxide (TiO 2 ). Enriched peptides were desalted as above but eluted in 200 μl of 80% ACN, 0.1% formic acid and dried under vacuum. Dried peptides were re-suspended in 20 μl of 0.1% formic acid for LC-MS/MS analysis. Samples (4 μl) were injected in duplicate onto an EASY-nLC 1000 (mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in ACN) connected to a Q-Exactive Plus (Thermo Scientific) equipped with a nano-electrospray ion source. Raw MS/MS data was searched using the Sorcerer 2TM-SEQUEST algorithm (Sage-N Research) using default peak extraction parameters. Post-search analysis was performed using Scaffold 4 (Proteome Software) with protein and peptide probability thresholds set to 95% and 90%, respectively, and one peptide required for identification, and spectra manually validated. Phosphorylation-site localization was determined using Scaffold PTM version 2.1.3 and phosphorylation sites had to have probabilities greater than 90%. Detection of direct PKG1 phosphorylation of TSC2. These assays used a TSC2 knockout HEK293 cell line generated in our laboratory. In brief, 1 million HEK293T cells were plated overnight in six-well plate with antibioticfree DMEM supplemented with 10% FBS. The following day, 4 μg of custom Sanger CRISPR plasmid for TSC2 (All-in-one, ready-to-use Cas9 and guide RNA (U6gRNA-Cas9-2A-GFP) expression plasmid against target site GTCGCGGATCTGTTGCAGCCGG, HS0000020001, Sigma) was transiently transfected using Lipofectamine 3000 (Invitrogen). The subsequent day, the medium was replaced with DMEM supplemented with 10% FBS and 1% antibiotics, and the day after GFP + cells were FACS-sorted to obtain TSC2 knockout HEK293T cells and assessed for knockout efficiency via immunoblotting. CRISPR TSC2 knockout HEK293 cells were cultured in DMEM supplemented with 10% FBS and 1% antibiotics. For PKG1-TSC2 kinase assays, TSC2 was reintroduced into knockout HEK293 cells grown to 50-60% confluence using an adenovirus expressing Flag-TSC2(WT) or Flag-TSC2(S1365A), cultured for 24 h, and the protein was isolated. TSC2(WT) or TSC2(S1365A) (either human TSC2(S1364A) or human TSC2(S1365A)) proteins were expressed in TSC2 knockout HEK293 cells delivered by plasmid or adenovirus, respectively, and then immunoprecipitated with Flag or HA magnetic beads (Sigma). Immune complexes were washed three times in lysis buffer and then washed twice in kinase buffer (25 mM HEPES, 10 mM magnesium acetate and 50 μM ATP) and incubated with 1 μg purified active PKG1 (Millipore) and 2 μCi [γ-32 P]ATP or 2 μCi [γ-33 P]ATP in 40 μl kinase buffer for 30 min at 30 °C. The reactions were stopped by washing twice in kinase buffer and boiling in gel loading buffer. Samples were then resolved in a 7.5% TGX gel (Bio-Rad), transferred to a nitrocellulose membrane and 32 P or 33 P incorporation was detected by autoradiography.
We also used the method developed previously 19 , which involves a genetically modified PKG1(M438G) that has been reported and validated previously 18 , that increases the ATP binding site so that a bio-orthogonal sulfonated ATPγS (N6-benzyl-ATP) can preferentially bind. TSC2 knockout HEK293 cells were seeded into 10-cm plates, infected with Flag-TSC2 or HA-TSC2, and lysates were obtained 24 h later in cell signalling lysis buffer. A 200 μl kinase reaction consisted of 25 mM Tris, 10 mM MgCl 2 , 1 mM 8-CPT-cGMP, 0.4 mM ATP, 6 mM GTP, 1 mM ATP (N6-benzyl-ATPγS) and 100 μl cell lysate 29 . Reactions further received 2 μg of PKG1(WT) or PKG1(M438G) or buffer to an equal final volume. The reaction was carried out at 30 °C for 1 h, then quenched with 20 mM EDTA and 5 mM p-nitrobenzyl mesylate to alkylate samples (1 h rotating at room temperature). Immunoprecipitation was carried out (using either Flag-or HA-coated beads) overnight at 4 °C, samples were eluted by boiling in sample buffer for 3 min and the precipitate analysed by immunoblot using a thiophosphate ester monoclonal antibody (Abcam). Statistical analysis. Data annotations (for example, mean ± s.d. or mean ± s.e.m.), the number of experiments and biological independent samples, analyses-including multiple comparisons tests-and absolute P values for comparisons are provided for each figure in the figure or the legend. The majority of summary data are presented as mean ± s.d., analysed using one-way or two-way ANOVAs and using Tukey or Sidak multiple pairwise comparisons tests. Statistical analyses were performed using Graphpad Prism software v.8 (2017). Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
The authors declare that the data supporting the findings of this study are available within the paper and the Supplementary Information. Numerical values corresponding to figures that describe the results from in vivo model studies are provided as separate Source 2a, 3d, 4c, e and Extended Data Fig. 1a . Other source data related to the study are available from the corresponding author upon reasonable request. Any reagents developed for this study, including novel plasmids, viral vectors and the Tsc2 knock-in mouse models can be made available upon direct request to the corresponding author. Fig. 2 | PKG1 activation enhances autophagic flux and this is required for anti-hypertrophic efficacy and leads to TSC2 phosphorylation at S1364 (human; 1365 mouse; 1366 rat). a, Immunoblot of LC3-II in NRCMs with and without BFA treatment to block autophagy by preventing lysosomal proteolysis. The relative increase in LC3-II expression without versus with BFA treatment indexes autophagic flux. An example blot is shown on the left, summary data on the right. n = 4 biologically independent experiments; data are mean ± s.d., two-way ANOVA with Tukey multiple pairwise comparisons test, P < 0.0001 for interaction between ±BFA and drug treatment; *P = 1.5 × 10 −5 , # P < 1 × 10 −6 , § P = 0.013, ‡ P = 0.0002 for within group comparison ±BFA; † P < 1 × 10 −6 versus each of the other groups with BFA . b, Effect of siRNA gene knockdown of Atg5 (siATG5) versus scrambled control (Scr-siRNA) on Nppb gene expression in NRCMs treated with ET1 with or without sildenafil. n = 6 biologically independent samples, data are mean ± s.d., one-way ANOVA and Tukey multiple comparisons test, † P < 1 × 10 −6 versus three groups in Scr-siRNA, # P < 1 × 10 −6 versus ET1 and sildenafil (Sil) in siATG5 group. c, Mass spectrometry identifies Tsc2 S1366 in rat (equivalent to human S1364 and mouse S1365) as a phosphorylation target of PKG1. Adult rat ventricular myocytes were exposed to cGMP to stimulate PKG1 activity and mass spectrometry was performed on three independent replicates. d, Summary of immunoblot experiment in Fig. 1e . MEFs treated with 8-bromo-cGMP with and without the PKG1 inhibitor DT3. n = 6 biologically independent samples, data are mean ± s.d., one-way ANOVA with post hoc Tukey test: † P = 0.00004 versus vehicle, ‡ P = 0.0004 versus cGMP. e, Immunoblot for TSC2 (antibody that recognizes the C terminus) in cardiomyocytes expressing native protein, or transduced with TSC2(WT), TSC2(S1365A) or TSC2(S1365E) using plasmid vector transfection. Expression levels were similar with each plasmid at twice the level of non-transduced cells. n = 4 biologically independent samples, data are mean ± s.d., one-way ANOVA with post hoc Tukey test, *P = 0.0004 versus control.
Extended Data
Extended Data Fig. 3 | PKG1 is activated by ET1 in rat cardiomyocytes and results in TSC2 phosphorylation detected by a human TSC2(S1364) antibody in cells expressing human TSC2(WT) but not human TSC2(S1364A) or TSC2(S1365A); this phosphorylation occurs by direct modification of TSC2 by PKG1α. a, PKG1 activation in cardiomyocytes expressing human TSC2(WT), TSC2(S1365A) or TSC2(S1365E) and stimulated with ET1 (10 nM) versus vehicle for 48 h. Data are mean ± s.d., n = 18 biologically independent samples, two-tailed unpaired Student's t-test. b, From same experiment, PKG1 activation is found to be independent of the form of TSC2 expressed; n = 6 biologically independent samples, box and whisker and raw data plots. Data normalized to median for wild type (without ET1); P = 0.0004 for ET1 effect, P > 0.8 for TSC2 genotype effect by two-way ANOVA. c, Summary data for phosphorylated/total human TSC2(S1364) from the rat cardiomyocyte ET1-stimulation experiment shown in Fig. 1f . Data are mean ± s.d., n = 6 biologically independent samples from three experiments, one-way ANOVA with Tukey multiple comparisons test, # P = 0.003 versus TSC2(S1365E), P = 0.0003 versus TSC2(S1365A). d, Antibody raised against TSC2(S1365) (mouse) (equivalent to human TSC2(S1364)) shows increased TSC2 phosphorylation in rat cardiomyocytes transfected with human TSC2(WT), but not cells expressing human TSC2(S1365A) or human TSC2(S1365E). Summary from three independent replicates yielding n = 6 biologically independent samples, data are mean ± s.d., one-way ANOVA with Tukey multiple comparisons test, # P = 0.0002 versus TSC2(S1365E), P = 0.0007 versus TSC2(S1365A). The results are identical to those using mouse TSC2(S1365) (human TSC2(S1364)) mutants displayed in Fig. 1i , indicating that mutations at either serine (human sequence: S1364 or S1365; mouse sequence S1365 or 1366) prevents phosphorylation of the other and/or its detection by the phosphorylation-specific antibody. e, Direct TSC2 phosphorylation by recombinant PKG1α detected by autoradiography on human Flag-TSC2(WT) and Flag-TSC2(S1365A). Experiments were replicated three times (n = 6 biologically independent samples) with identical results. The result is identical to that in Fig. 1j with human HA-TSC2(S1364A). f, Direct TSC2 phosphorylation by PKG1α in lysates from TSC2 knockout HEK293 cells expressing human TSC2(WT) or human HA-TSC2(S1364A) or human Flag-TSC2(S1365A), PKG1α(M438G), and N6-benzyl-ATPγS, and probed for thiophosphate ester. Top, data with human TSC2(S1364) mutated; bottom, with human TSC2(S1365) mutated. The results are identical. n = 6 biologically independent samples for each assay.
Extended Data Fig. 5 | Effects of TSC2(S1365A) and TSC2(S1365E) on mTORC1 activation in response to phenylephrine; PKG1 activation of autophagy requires in part its phosphorylation of TSC2; and amplification of mTORC1 stimulation in cells expressing S1365A TSC2 mutation requires RHEB. a, NRCMs expressing TSC2(WT), TSC2(S1365A) or TSC2(S1365E) (human TSC2(S1365) was modified) and exposed to vehicle or phenylephrine (PE, 100 mM) for 48 h. Left, example immunoblot for phospho-p70S6K and total protein. Right, summary data, normalized to TSC2(WT) without phenylephrine. Data are mean ± s.d., n = 6 biologically independent samples, Kruskal-Wallis Test with Dunn's multiple comparisons test, *P = 0.003 versus corresponding vehicle; † P = 0.0013 versus TSC2(S1365E) and ET1. b, Top, example immunoblots for LC3-II and p62 in lysates obtained from Tsc2 knockout MEFs transfected with either human TSC2(WT) or TSC2(S1364A) plasmids and then treated with ET1 (10 nM) with or without cGMP (50 μM). n = 3 biologically independent samples. Bottom, summary data, normalized to TSC2(WT) without cGMP and without ET1; data are mean ± s.d., one-way ANOVA with Tukey multiple comparisons test, *P = 0.01 versus TSC2(WT) without ET1 without cGMP, P = 0.02 versus TSC2(WT) and ET1 with cGMP, † P < 1 × 10 −6 versus TSC2(S1364A) without ET1 without cGMP and versus with ET1 with cGMP, # P = 2 × 10 −6 versus TSC2(WT) with ET1, ‡ P = 5 × 10 −5 versus TSC2(WT) and ET1 with cGMP, † † P = 1 × 10 −6 versus TSC2(WT) without ET1 without cGMP and versus ET1 with cGMP, **P = 1 × 10 −6 versus TSC2(WT) without ET1 without cGMP, § P = 0.002 versus TSC2(WT) with ET1, § § P < 1 × 10 −6 versus TSC2(WT) with ET1 with sildenafil. c, Summary results for Fig. 2d . Rat cardiomyocytes transfected with RHEB or scrambled (Scr) siRNA, transfected with TSC2(WT), TSC2(S1365E) or TSC2(S1365A) plasmids (human TSC2(S1365) modified) and stimulated with ET1 for 48 h. Effect of gene silencing of Rheb on RHEB protein expression (right) and on phosphorylated/total p70S6K protein expression (left). n = 4 biologically independent experiments, data are mean ± s.d., values normalized to TSC2(WT) treated with vehicle and scramble siRNA. Each plot was analysed by one-way ANOVA with pairwise Tukey multiple comparisons test, † P = 1 × 10 −6 versus corresponding scramble siRNA without or with ET1, one-way ANOVA with Tukey multiple comparisons test, *P = 1 × 10 −6 versus scramble siRNA and vehicle for TSC2(WT) and TSC2(S1365A), # P = 0.00002 versus scramble siRNA and ET1 for TSC2(WT) or TSC2(S1365A). Fig. 8 | Generation of Tsc2 S1365E/S1365E knock-in mice and impact on pressure-overload-induced mTORC1 activation, autophagy and autophagic flux in vivo. a, Strategy and guide RNA for CRISPR-Cas9 protocol to generate Tsc2 S1365E/S1365E knock-in mice. b, Summary data for Fig. 4f . Phosphorylated/total p70S6K (n = 6 biologically independent experiments), p62/α-tubulin and LC3-II/total protein (n = 4 biologically independent experiments, data are mean ± s.d., values are normalized to Tsc2 WT/WT sham), two-way ANOVA with Sidak's multiple comparisons test, *P < 1 × 10 −6 versus Tsc2 WT/WT sham, P = 0.0012 versus Tsc2 S1365E/WT with pressure overload, and P = 0.0001 versus Tsc2 S1365E/S1365E with pressure overload, † P = 0.0008 versus Tsc2 S1365E/WT sham, ‡ P = 0.001 versus Tsc2 S1365E/S1365E sham; for p62, # P ≤ 1 × 10 −6 versus all other groups, for LC3-II, § P = 0.018 and P = 0 . 0003 versus pressure overload Tsc2 S1365E/WT and pressure overload Tsc2 S1365E/S1365E , respectively, **P = 0.02 versus pressure overload Tsc2 S1365E/S1365E and P = 0.0002 versus sham, ## P < 1 × 10 −6 versus sham. c, Example immunoblot and summary results for Tsc2 WT/WT , Tsc2 S1365E/S1365E and Tsc2 S1365A/S1365A mice treated with BFA or vehicle. Myocardium was assayed for LC3-II, with higher expression in the presence of BFA, indicating greater autophagic flux. Summary data, values normalized to Tsc2 WT/WT vehicle, data are mean ± s.d., n = 4 biologically independent experiments; two-way ANOVA: P < 1 × 10 −6 for BFA effect, P = 0.003 for Tsc2 genotype effect, and P = 0 . 002 for interaction; Sidak's pairwise multiple comparisons test: *P = 0.0008 versus Tsc2 WT/WT vehicle, † P < 1 × 10 −6 versus Tsc2 S1365E/S1365E vehicle and P = 0.008 versus Tsc2 S1365A/S1365A + BFA, ‡ P = 0.05 versus Tsc2 WT/WT + BFA. final data set. All animals assigned to particular treatment groups for the In vivo studies were used for analysis. If a treatment was employed, the animals were used by intention to treat. Reproducibility was also enhanced by having several investigators perform similar assays.
The following list identifies what was done to assure reproducibility for each experiment in this study: Figure 1A , 1B: Based on multiple mice (n=24 total, assigned randomly to 4 groups), all data used and results highly reproducible. Figure 1C :
Individual cell images for each condition with overall variance depicted and all data displayed. Results were highly reproducible. Figure 1E (upper) Highly reproducible result, performed by several laboratory members. Figure 1E (lower), 1F, 1G: Based on all mice used in study displayed in Figure 1A . No data excluded. Results highly reproducible. Figure 1H : Sample size of n=12 per group provided sufficient power. Random selected tissues, no bias. Tissue all processed identically. Figure 1I : Reproduced x3 with no disparities, also reproduced with another mutation (x3, n=6 total). Very consistent. Figure 1J : All technical replicates and biological replicates have demonstrated the identical findings. This was repeated x6. Figure 2A : Very strong group differences, and study now shown in entirety using two different serine mutations, fully reproducible. Figure 2B : All cell culture studies used, and data shown in paper demonstrates identical responses with either of the serine mutations. Figure 2C : Same situation as in Figure 1C , all cell data shown, despite variance between cells, group differences are marked, and reproduced. Figure 2D : Data consistent with other results previously shown (without siRNA to Rheb), and technically certified runs used. Very reproduced. Figure 2E : Data from 5 separate experiments, 2 independent investigators with very consistent results. Very reproducible. Figure 3B : All data used from population studied in time course and drug trial. Figure 3C ,3D: Example in 3C is confirmed as highly reproducible in 3D. Despite interanimal variance, statistical differences are marked. Figure 3E : Nearly binary results of assay that was very reproducible, all gels for this study were utilized. Figure 3F : Performed in all surviving animals at end-of-study, no bias, and consistent with sample size in other assays from mouse study. Figure 4A : While this entire study was done once, the results were marked, and sample size sufficient to power difference detection. Figure 4B : Very reproducible results as demonstrated by highly disparate effects among groups. Figure 4C ,4D: Example echocardiography which is consistent with mean results demonstrated in Figure 4D . Figure 4F : Same animals used to generate imaging and functional data were used for immunoblots. Results marked and reproducible. Figure 4G : Same explanation as provided for Figure 4F .
Extended Data 1A-1C: Same experiment shown in Figure 1A , 1B, and same explanation applies. Extended Data 1D: Experiment performed once, though results were striking and differences highly significant. This is further consistent with subsequent data shown in Figure 3F in which protein aggregation was assayed in a different manner. Extended Data 2A:
Experiment performed once, all data shown. Little variance in independent samples, supports reproducibility. Extended Data 2B:
Experiment performed with multiple biological replicates, PCR results show marked differences. Extended Data 2D:
Relates to Figure 1E Upper. Extended Data 2E:
Performed multiple times by multiple investigators, panel here shows high concordance of results, reproducible. Extended Data 3A:
Given variance, we performed study with larger sample size, providing robust power for interpretation. Extended Data 3B:
While there is some inter-group variance, overall analysis shows very consistent result in each group. Extended Data 3C:
Relates to Figure 1E lower.
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was previously determined. We present a novel antibody in this study as well, and we validated this using KO models, mutated protein studies where the phosphorylation site is deleted.
Validation
All of the commercial antibodies were previously well described and validated. The antibody for S1365 TSC2 phosphosphorylation obtained from NovoPro had not been previously reported. Validation was performed in MEFs lacking the protein, with re-expression of the protein with and without site mutations at the S1365 that impact phosphorylation of the residue (e.g. S1365A which prevents it), and then with and without kinase activation (PK). These validation studies are presented in the manuscript. Each commercial antibody was validated by the manufacturer as noted at their website. The information for this validation is listed for each antibody used in the study in a separate Antibody Validation Table Document .
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)
We used mouse embryonic fibroblasts (standard cell line, or MEFs with TSC2 knocked-out) provided from the laboratory of Brendan Manning. These have been used in many prior studies and are well established models. We also generated a new HEK TSC2 KO cell line and present these methods and line details in the revision. Other cells are primary isolated neonatal ventricular myocytes from rat -so not a cell line per se. Methods for this preparation are well established and referenced.
Authentication
We did not perform specific authentication procedures for the cells used in this study, as the cell lines are well established and widely used, and the primary isolations are not cell lines.
Mycoplasma contamination
Our cultured cells are assessed for evidence of bacterial contamination in a more general manner, as part of maintenance of our incubator systems and being sure we have not infectious contamination. However, we did not specifically test for mycoplasma.
Commonly misidentified lines (See ICLAC register)
None were used.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
For all in vivo studies the mice were aged around 2-3 months at the time of pressure overload or sham surgeries. Wild type C57 black mice were purchased from Charles River. TSC2 SA and SE knock in mice were designed by our lab and generated at the Johns Hopkins Mouse Transgenics Core using CRISPR/Cas9 technology. They are also raised in the C57 black background. All protocols and procedures were approved by the Johns Hopkins IUCAC. The studies were in compliance with all ethical regulations. Both male and female mice were utilized in this study.
Wild animals
The study did not involve the use of wild animals.
Field-collected samples
The study did not involve the use of samples collected from the field.
Human research participants
Policy information about studies involving human research participants
Population characteristics
De-identified human tissue was made available to study through an agreement between Johns Hopkins (David Kass, PI) and University of Pennsylvania (Ken Margulies, PI). Patient information including demographics, clinical diagnosis and hemodynamic, treatment, and other relevant clinical parameters are provided. Left ventricular tissue from non-failing control hearts are obtained from organ donors whose heart was not used for transplantation (Gift of Life). The research is approved by both Johns Hopkins and Univ. Pennsylvania respective IRBs. There were two cohorts of samples. For the non-failing controls, the age was 52.8 ± 15.4, 6 males, 6 females, LV function in normal range, and no clinical history of heart failure; for the heart failure group, the mean age was 51.3 ±12.1, 8 males, 4 females, all with severe dilated non-ischemic cardiomyopathy who then all underwent subsequent cardiac transplantation.
Recruitment
The samples are obtained from either deceased patients or patients receiving a heart transplant -the latter are alive and recruited from those subjects receiving transplantation at the University of Pennsylvania. The particular samples reported in this study were randomly taken from a database of many such patients in each group, selected purely based on their inclusion in either the control or heart failure cohort. Informed consent was obtained from failing heart human tissue donors. The family or legal representative provided consent for organ harvesting from deceased donor controls.
